Efficacy and safety of Ascoril expectorant and other cough formula in the treatment of cough management in paediatric and adult patients--a randomised double-blind comparative trial.

The present study was undertaken to study the comparative safety and efficacy of two cough formulas viz, Ascoril expectorant and other cough formula in the management of cough associated with respiratory disorders. Fifty patients having cough associated with various respiratory disorders like bronchitis and upper or lower respiratory tract infections were randomly divided into 2 equal groups and were treated with one of the two cough formulas viz, Ascoril cough formula and other cough formula in double-blind manner over a period of 15 days. The evaluation of improvement was carried out by a rating scale using three clinical parameters--cough, sputum and breathlessness. The physicians were asked to rate the effectiveness of the therapy and patients were asked to rate the acceptability of therapy using pre-defined operational criteria. It was observed that the improvement and symptom relief was almost immediate, quicker and better in the group receiving Ascoril as compared to other group. On effectiveness parameter, 96% of the physicians rated Ascoril as having either 'very high effectiveness or high effectiveness' as opposed to only 34% of the physicians who rated other cough formula as having 'high' or 'very high effectiveness'. While on parameter of acceptability, 96% of the patients rated acceptability of Ascoril as 'high' or 'good' as opposed to only 24% of the patients who rated other cough formula 'high' or 'good'. The findings of this study suggests that Ascoril cough formula has better efficacy as well as better patient acceptability. Thus, Ascoril cough formula is superior to other cough formula in management of cough associated with respiratory disorders.

Evaluación comparativa del tratamiento con yodo y bromhexina en la queratoconjuntivitis sicca / A comparative evaluation of the keratoconjuntivitis sicca treatment between iodine and bromhexine

Presentamos aqui los resultados de un estudio clinico, con la administracion de yodo en pacientes con Queratoconjuntivitis Sicca (QCS) o Sindrome de Sjogren (SS), con el fin de estimular su secreción lagrimal, más del 80%respondieron al tratamiento satisfactoriamente, asi como el 71%de los tratados con bromhexina (grupo control), conocida ya como lacrimoestimulantes. Ambos tratamientos mejoraron la xerostomia en la mayoria de pacientes son (SS)